Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy

Cell Therapy for Duchenne Muscular Dystrophy Capricor Therapeutics develops deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Deramiocel The therapy is designed to address skeletal-muscle and cardiac disease through immunomodulatory, antifibrotic, and regenerative signaling. HOPE-3 Evidence The...

Recent company news

CAPRCapricor Therapeutics2026-10-05 13:00 EST

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

CAPRCapricor Therapeutics2026-09-17 12:30 EST

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

CAPRCapricor Therapeutics2026-08-24 13:25 EST

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

CAPRCapricor Therapeutics2026-08-13 20:05 EST

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

CAPRCapricor Therapeutics2026-08-10 12:30 EST

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

Stock data

Close: 7.75 USD
Market cap: 1.58B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy

Related news

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Capricor Therapeutics